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Low birth weight as a potential 
risk factor for severe COVID‑19 
in adults
F tima Crispi1,6*, Francesca Crovetto1,6, Marta Larroya1, Marta Camacho1, Marta Tortajada1, 
Oriol Sibila2, Joan Ramon Badia2, Marta López1, Kilian Vellvé1, Ferran Garcia3, Antoni Trilla4, 
Rosa Faner2, Isabel Blanco2, Roger Borr s5, Alvar Agustí2,6 & Eduard Gratacós1,6
The identification of factors predisposing to severe COVID‑19 in young adults remains partially 
characterized. Low birth weight (LBW) alters cardiovascular and lung development and predisposes to 
adult disease. We hypothesized that LBW is a risk factor for severe COVID‑19 in non‑elderly subjects. 
We analyzed a prospective cohort of 397 patients (18–70 years) with laboratory‑confirmed SARS‑
CoV‑2 infection attended in a tertiary hospital, where 15% required admission to Intensive Care Unit 
(ICU). Perinatal and current potentially predictive variables were obtained from all patients and LBW 
was defined as birth weight ≤ 2.500 g. Age (adjusted OR (aOR) 1.04 [1–1.07], P = 0.012), male sex (aOR 
3.39 [1.72–6.67], P < 0.001), hypertension (aOR 3.37 [1.69–6.72], P = 0.001), and LBW (aOR 3.61 [1.55–
8.43], P = 0.003) independently predicted admission to ICU. The area under the receiver‑operating 
characteristics curve (AUC) of this model was 0.79 [95% CI, 0.74–0.85], with positive and negative 
predictive values of 29.1% and 97.6% respectively. Results were reproduced in an independent 
cohort, from a web‑based survey in 1822 subjects who self‑reported laboratory‑positive SARS‑CoV‑2 
infection, where 46 patients (2.5%) needed ICU admission (AUC 0.74 [95% CI 0.68–0.81]). LBW seems 
to be an independent risk factor for severe COVID‑19 in non‑elderly adults and might improve the 
performance of risk stratification algorithms.
COVID-19 is a mild or asymptomatic condition in the majority of patients, but in up to 1–2% it may result in 
severe disease and  death1,2. Older age, male sex and coexisting conditions are the main risk factors described so 
far for severe COVID-19  disease3–8. However, a small proportion of young and apparently healthy adults may 
eventually require critical care. There is a need for comprehensive models that identify factors associated to the 
risk of severe forms of COVID-199.
The association between low birth weight (LBW) and adult health has long been  recognized10–12. LBW, defined 
as ≤ 2500 g13,14, can result from fetal growth restriction, prematurity or  both13. Fetal growth restriction has been 
associated with increased cardiovascular  mortality10,15, lower lung functional  capacity16–18 and increased res-
piratory  morbidity18,19 in adulthood. Likewise, prematurity has been described as a risk factor for suboptimal 
 cardiovascular20 and  lung21 development and a greater predisposition to heart  failure22 and lung  disease23 later 
in life. For studies in adults, birth weight is an accessible and robust surrogate for fetal growth restriction and 
preterm births, and a strong predictor of short and long-term  morbidity24.
From the above observations, we hypothesized that LBW could increase the risk of developing severe illness 
in non-elderly adults with COVID-19. To test this hypothesis, we designed a prospective study in confirmed 
COVID-19 patients (18–70 years) admitted to our institution, a public, tertiary, referral, university hospital in 
Spain (development dataset) and validated the model in an independent cohort of self-reported laboratory-
confirmed COVID-19 subjects recruited through a web-based survey (validation dataset).
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Results
Development dataset. Figure 1 (left panel) presents the CONSORT diagram of the testing cohort. Out 
of 516 potentially eligible patients (with laboratory-confirmed SARS-CoV-2 infection by real time polymerase 
chain reaction (RT-PCR) of nasopharyngeal swab samples) during the study period, the development cohort 
included 397 patients with available perinatal information (77%). Based on clinical assessment of severity, 98 
patients (24.7%) followed home hospitalization care and 299 (75.3%) were hospitalized, 60 of whom (20%) were 
eventually taken care of in the Intensive Care Unit (ICU) (25 (42%) required mechanical ventilation and none 
died). Table 1 displays the characteristics of the 337 non-critically ill patients (home hospitalization (n = 98) or 
in hospital (n = 239)) with those treated in the ICU (n = 60). The latter were older, more frequently males, had a 
higher body mass index (BMI) and a higher prevalence of hypertension. Of note, they were also born with LBW 
(18.3 vs. 9.5%, p = 0.041) and suffered fetal growth restriction (25 vs. 14.8%, p = 0.043) more often. Individuals 
born with LBW had a higher probability for ICU admission as compared with those with normal birth weight 
(Fig. 2).
Table 2 displays crude and adjusted Odds Ratio (aOR) for ICU admission. In the multivariate model, age 
(aOR 1.04 [1–1.07], P = 0.012), male sex (aOR 3.3 [1.72–6.67], P < 0.001), hypertension (aOR 3.4 [1.69–6.72], 
P = 0.001), and LBW (aOR 3.61 [1.55–8.43], P = 0.003) remained independent predictors of ICU. As shown in 
Fig. 3 (left), the area under the receiver-operating characteristics curve (AUC) for predicting ICU admission was 
0.79 (95% CI, 0.74–0.85). The model had a sensitivity of 91.7%, specificity of 60.2%, positive predictive value 
(PPV) of 29.1% and negative predictive value (NPV) of 97.6% (Table 3).
Validation dataset. Figure 1 (right panel) presents the CONSORT diagram of the validation dataset. We 
received 9320 responses of subjects aged 18 to 70 years who referred symptoms suggestive of COVID-19. Among 
them, 1822 self-reported COVID-19 confirmed by RT-PCR. A total of 1215 of them (67%) reported mild symp-
toms and did not require hospital admission whereas 607 (33%) were hospitalized of whom 46 (8%) patients 
required ICU admission (30 of them (65% of ICU patients) were mechanically ventilated, and one male patient 
(2% of ICU patients) died at the age 68 years as reported later by her daughter.
Table 4 shows the characteristics of the 1776 non-critically ill patients (treated at home (n = 1215) or in hospi-
tal (n = 561)) with those treated in the ICU (n = 46). Like we observed in the developing cohort, ICU patients in 
the validation dataset were older, more frequently males, had a higher BMI and a higher prevalence of hyperten-
sion. Importantly, again, they were born with LBW (19.6 vs. 7.3%, p = 0.006) and suffered fetal growth restriction 
(26.1 vs. 12.4%, p = 0.010) more often. In this validation dataset, the prevalence of prematurity was also higher 
in ICU patients (23.9 vs. 10.9%, p = 0.011).
The model obtained in development dataset was applied to the validation dataset, obtaining an AUC of 0.74 
(95% CI 0.68–0.81) (Fig. 2, right panel), with a sensitivity of 73.9%, specificity of 67.3%, PPV of 5.5% and NPV 
of 99% (Table 3).
Discussion
This study provides evidence that recording birth weight might improve the prognostic stratification of COVID-
19 in non-elder patients. Most young patients present mild forms of COVID-19, but a small proportion might 
require admission to ICU for severe  complications3–8, which is clearly associated to non-obvious predisposing fac-
tors. Early interventions in COVID-19 have demonstrated to reduce  mortality4,6. Consequently, the identification 
of predisposing factors –particularly in a priori non high-risk subjects- might allow early therapeutic measures 
eventually preventing serious evolution to serious illness. In this study we evaluated an innovative approach 
by studying early life risk factors not usually taken into account in current clinical practices. Birth weight is 
one of the most universally recorded information for any given individual and self-recalled birth weight has 
516 eligible patients with  




Developing dataset:  
397 patients (77%) 
98 home (25%) 299 hospitalized (75%) 
60 ICU admission (20%) 239 non ICU admission (80%) 
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Developing dataset Validation dataset
9,320 responses with potential COVID-19 
Figure 1.  CONSORT diagram of the study.
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Table 1.  Characteristics of participants in the development cohort by ICU admission. ICU intensive care 
unit, NSAIDs non-steroidal anti-inflammatory drugs, ACE angiotensin-converting enzyme. *P-value for the 
comparison of ICU admission vs. no ICU admission. a Other viral infections including HIV and/or hepatitis 
B or C. b Psychiatric disorders including depression, bipolar disorder, schizophrenia and anxiety requiring 
treatment.
All population (N = 397) No ICU admission (N = 337) ICU admission (N = 60) P value*
Demographic and clinical characteristics in adulthood
Mean age (± SD)—years 47 ± 12.2 46 ± 12.2 53 ± 10.1  < 0.001
Female—no. (%) 197 (49.6) 183 (54.3) 14 (23.3)  < 0.001
Mean body mass index (± SD)—kg/m2 26.9 ± 5 26.6 ± 5 28.6 ± 4.8 0.005
Current smoker—no. (%) 27 (6.8) 24 (7.1) 3 (5) 0.394
Ex-smoker—no. (%) 129 (32.5) 104 (30.9) 25 (41.7) 0.069
Coexisting conditions—no. (%)
Hypertension 66 (16.6) 40 (11.9) 26 (43.3)  < 0.001
Cardiovascular disease 16 (4) 12 (3.6) 4 (6.7) 0.211
Diabetes mellitus 32 (8.1) 26 (7.7) 6 (10) 0.350
Obesity 98 (24.7) 84 (24.9) 14 (23.3) 0.467
Dyslipidemia 31 (7.8) 23 (6.8) 8 (13.3) 0.077
Chronic lung disease 37 (9.3) 33 (9.8) 4 (6.7) 0.312
Chronic kidney disease 20 (5) 14 (4.2) 6 (10) 0.064
Autoimmune disease 12 (3) 10 (3) 2 (3.3) 0.564
Malignancy 28 (7.1) 22 (6.5) 6 (10) 0.235
Thyroid disorders 25 (6.3) 21 (6.2) 4 (6.7) 0.540
Other viral  infectionsa 11 (2.8) 8 (2.4) 3 (5) 0.223
Psychiatric  disordersb 23 (5.8) 19 (5.6) 4 (6.7) 0.469
Previous hospital admission within the 
last 12 months—no. (%) 32 (8.1) 27 (8) 5 (8.3) 0.548
Drugs within last 15 days before COVID-19 diagnosis—no. (%)
NSAIDs 142 (35.8) 120 (35.6) 22 (36.7) 0.492
ACE inhibitors 27 (6.8) 21 (6.2) 6 (10) 0.208
Corticoids 12 (3) 11 (3.3) 1 (1.7) 0.436
Perinatal and childhood characteristics
Mean birth weight (± SD)—g 3302 ± 666 3296 ± 635 3335 ± 826 0.728
Low birth weight—no. (%) 43 (10.8) 32 (9.5) 11 (18.3) 0.041
Fetal growth restriction—no. (%) 65 (16.4) 50 (14.8) 15 (25) 0.043
Prematurity—no. (%) 28 (7.1) 23 (6.8) 5 (8.3) 0.420
Childhood lung disease—no. (%) 75 (18.9) 67 (19.9) 8 (13.3) 0.155
Asthma 42 (10.6) 39 (11.6) 3 (5) 0.229
Bronchitis 20 (5) 16 (4.7) 4 (6.7) 0.126
Other lung disease 13 (3.3) 12 (3.6) 1 (1.7) 0.579
Figure 2.  Adjusted probability prediction for ICU admission in normal vs. low birth weight individuals 
computed with multivariate logistic regression model. For further explanations, see text.
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demonstrated to be a reliable information, particularly in subjects born after the  1960s41. If confirmed in future 
studies that LBW identifies high risk for complicated COVID-19, this should be included in initial assessment 
of non-elder infected subjects and would offer opportunities for early interventions to prevent complications.
Previous studies. Despite the large number of studies on prognostic factors for severe COVID-193–8,25–36, to 
our knowledge no previous study has investigated the predictive role of early life events as a risk factor for severe 
COVID-19 in adulthood. Results confirmed our working hypothesis, which was aligned with a long-standing 
research line in this  field11,12,18,19,37. Besides, results confirmed previous studies showing a strong predictive value 
for severe COVID-19 of older age, male sex and coexisting conditions such as  hypertension3–8,25–31. The fact 
that we studied non-elderly adults (≤ 70 years) may have limited the identification of significant associations 
with other reported coexisting conditions such as chronic lung  disease2,6–8,27,  diabetes2–5,7,8,25,26,30,32,  obesity8,31,33 
or  cancer3,34. Current or previous smoking  status35 and chronic treatment with ACE  inhibitors36 were not asso-
Table 2.  Odds Ratios for ICU admission for COVID-19 in the developing cohort. To obtain ICU admission 
probability calculate  elogit/(1 + elogit). ICU intensive care unit, OR odds ratio, aOR adjusted odds ratio, CI 
confidence interval.
Univariate analysis Multivariate analysis
OR (95% CI) p-value aOR (95% CI) p-value Beta coefficient
Age, in 1-year unit 1.06 (1.03–1.09)  < 0.001 1.04 (1–1.07) 0.012 0.03963
Sex: male vs. female 3.9 (2.07–7.37)  < 0.001 3.39 (1.72–6.67)  < 0.001 1.16734
Body mass index, in 1 kg/m2 unit 1.08 (1.02–1.13) 0.005
Smoker or ex-smoker: yes vs. no 1.43 (0.82–2.48) 0.206
Hypertension: yes vs. no 5.68 (3.09–10.43)  < 0.001 3.37 (1.69–6.72) 0.001 1.23937
Cardiovascular disease: yes vs. no 1.93 (0.6–6.21) 0.268
Diabetes mellitus: yes vs. no 1.33 (0.52–3.38) 0.550
Obesity: yes vs. no 0.9 (0.5–1.75) 0.792
Chronic lung disease: yes vs. no 0.8 (0.1–6.61) 0.835
Malignancy: yes vs. no 1.59 (0.62–4.1) 0.337
Low birth weight: yes vs. no 2.14 (1.01–4.52) 0.046 3.61 (1.55–8.43) 0.003 1.10971
Fetal growth restriction: yes vs. no 1.91 (0.99–3.69) 0.053
Prematurity: yes vs. no 1.24 (0.45–3.4) 0.675
Childhood lung disease: yes vs. no 0.62 (0.28–1.37) 0.236
Constant − 4.95673
Figure 3.  Receiver-operating characteristics curves for ICU admission in a multivariate model that includes 
age, sex, hypertension and low birth weight both in the development cohort (left) and validation dataset (right). 
For further explanations, see text.
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ciated with COVID-19 severity in our dataset. We acknowledge that other unstudied confounders may have 
interfered our results.
Interpretation of novel findings. Our results suggest that LBW is an independent risk factor for severe 
COVID-19 in adulthood. This finding is consistent with previous epidemiological and experimental studies sup-
porting the developmental origin of adult diseases. Adverse in utero environment induces permanent changes in 
Table 3.  Predictive accuracy of a multivariate model that includes age, sex, hypertension and low birth weight 
for ICU admission for COVID-19 in the developing cohort and validation dataset. ICU intensive care unit, 
PPV positive predictive value, NPV negative predictive value. a According to the logistic regression model, 
criteria positive is defined as a probability greater than 10.554%.
Patients admitted to ICU Patients not admitted to ICU Total patients Predictive value
Developing cohort N = 60 N = 337 N = 397
Criteria  positivea 55 true positive (29.1%) 134 false positive (70.9%) 189 PPV, 29.1%
Criteria negative 5 false negative (2.4%) 203 true negative (97.6%) 208 NPV, 97.6%
Sensitivity 91.7%
Specificity 60.2%
Validation dataset N = 46 N = 1780 N = 1826
Criteria  positivea 34 true positive (5.5%) 582 false positive (94.5%) 616 PPV, 5.5%
Criteria negative 12 false negative (1.0%) 1198 true negative (99.0%) 1210 NPV, 99.0%
Sensitivity 73.9%
Specificity 67.3%
Table 4.  Characteristics of COVID-19 patients in the validation dataset by ICU admission. ICU intensive care 
unit. *P-value for the comparison of ICU admission vs. no ICU admission. a Psychiatric disorders including 
depression, bipolar disorder, schizophrenia and anxiety requiring treatment.
All population 
(N = 1822)
No ICU admission 
(N = 1776) ICU admission (N = 46) P value*
Demographic and clinical characteristics in adulthood
Mean age (± SD)—years 46 ± 11.5 46 ± 11.5 52 ± 9.1  < 0.001
Female—no. (%) 1255 (68.9) 1239 (69.8) 16 (34.8)  < 0.001
Mean body mass index (± SD)—kg/m2 25 ± 4.9 24.9 ± 4.8 28.9 ± 6.3  < 0.001
Current smoker—no. (%) 132 (7.2) 130 (7.3) 2 (4.3) 0.340
Ex-smoker—no. (%) 702 (38.5) 682 (38.4) 20 (43.5) 0.290
Coexisting conditions—no. (%)
Hypertension 218 (12) 208 (11.7) 10 (21.7) 0.041
Cardiovascular disease 55 (3) 55 (3.1) 0 (0) 0.240
Diabetes mellitus 49 (2.7) 46 (2.6) 3 (6.5) 0.124
Obesity 224 (12.3) 210 (11.9) 14 (30.4) 0.001
Dyslipidemia 97 (5.3) 95 (5.3) 2 (4.3) 0.552
Chronic lung disease 200 (11) 196 (11) 4 (8.7) 0.419
Chronic kidney disease 17 (0.9) 16 (0.9) 1 (2.2) 0.354
Autoimmune disease 93 (5.1) 91 (5.1) 2 (4.3) 0.580
Malignancy 33 (1.8) 32 (1.8) 1 (2.2) 0.573
Thyroid disorders 125 (6.9) 120 (6.8) 5 (10.9) 0.204
Psychiatric  disordersa 61 (3.3) 61 (3.4) 0 (0) 0.205
Perinatal and childhood characteristics
Mean birth weight (± SD)—g 3390 ± 606 3393 ± 595 3283 ± 935 0.432
Low birth weight—no. (%) 128 (7.6) 129 (7.3) 9 (19.6) 0.006
Fetal growth restriction—no. (%) 233 (12.8) 221 (12.4) 12 (26.1) 0.010
Prematurity—no. (%) 205 (11.3) 194 (10.9) 11 (23.9) 0.011
Childhood lung disease—no. (%) 237 (13) 233 (13.1) 4 (8.7) 0.826
Asthma 143 (7.8) 141 (7.9) 2 (4.3) 0.309
Bronchitis 47 (2.6) 46 (2.6) 1 (2.2) 0.340
Other lung disease 47 (2.6) 46 (2.6) 1 (2.2) 0.666
6
Vol:.(1234567890)
Scientific Reports |         (2021) 11:2909  | https://doi.org/10.1038/s41598-021-82389-9
www.nature.com/scientificreports/
the structure, function and metabolism of the developing fetal organs. Most developmental changes of early life 
persist in the long term which leads to a greater risk of disease in  adulthood10,11. It is suggested that fetal adap-
tation to perinatal events represents a ‘first hit’ leading to latent susceptibility, which combined with a ‘second 
hit’ later in life could increase the risk for adult  diseases10,11. This notion has been consistently demonstrated 
in experimental  research38, but evidence in humans is limited. The COVID-19 pandemic represents a unique 
opportunity to study the response of a significant number of individuals born LBW to a specific and well-defined 
stressor.
LBW has been consistently associated with increased adult cardiovascular mortality, hypertension, metabolic 
syndrome, diabetes and lung  morbidity10–12,15–21. LBW can be a result of being born too small—fetal growth 
restriction- and/or too early—prematurity. Fetal growth restriction is caused by placental insufficiency leading 
to a sustained reduction in fetal oxygen and nutrient  supply11. This triggers an adaptive fetal response includ-
ing cardiovascular  remodeling12,39, increased blood  pressure12, altered lipoprotein profile, lost of nephrons, and 
disturbed pulmonary alveolarization and vascular  growth11. In prematurity, key developmental stages have to 
take place ex utero in non-physiological  conditions40 leading to cardiovascular hypertrophy and impaired lung 
development, insulin sensitivity and bone  density20–22,40.
Strengths and limitations. This study has some strengths and limitations that merit comment. Among 
the strengths, we prospectively collected information spanning the full COVID-19 clinical spectrum, from mild 
to hospitalized and ICU patients. Likewise, we validated our observations in an independent dataset. Finally, 
we included only non-elderly subjects (< 70  years) to avoid the potential confounding effect of age-related 
comorbidities. The study sample size was too small to assess the predictive value of LBW across age ranges. We 
acknowledge that the evidence here presented should be validated in another prospective hospital cohort. We 
opted for an online survey to shorten validation time. We acknowledge also a potential selection bias since there 
were virtually no deaths in our study population. Firstly, mortality rate for COVID-19 was very low in our hospi-
tal (8%, 194/2425) with most cases occurring in subjects > 70 years-old. Secondly, we tried to contact all COVID-
19 patients identified in the EMRs, but a few very severe cases were directly intubated and died preventing the 
interview for the study. In addition, we acknowledge the potential inaccuracy of the perinatal data obtained 
by interview or online survey. However, self-reported birth weight has demonstrated to be a good surrogate of 
adverse in utero environment, particularly in non-elderly  subjects41. Although the prevalence of LBW in our 
study populations lie within the range reported by recent international and national  estimates42, we acknowledge 
that a selection bias cannot be fully discarded. Finally, we acknowledge that future studies might unveil non-
identified confounders not considered in the design of this study that might have affected the present results.
Conclusions
Our data suggest that low birth weight increases the risk of severe COVID-19 in non-elderly adults. This new 
information further supports the importance of early life events in adult diseases. If confirmed in future studies, 
LBW should be considered in frisk stratification algorithms for COVID-19.
Methods
Development dataset. Study design, population and ethics. Prospective observational cohort that in-
cluded non-elderly adults (aged 18 to 70 years) consecutively attended at Hospital Clínic of Barcelona from 
March 25 to April 25, 2020 with laboratory-confirmed SARS-CoV-2 infection by real time polymerase chain 
reaction (RT-PCR) of nasopharyngeal swab samples. Sample size was determined by the time window of oppor-
tunity of the study. Criteria for hospital admission (COVID-19 pneumonia) and therapeutic management while 
in hospital followed the in-house protocols. The primary outcome of the study was admission to the ICU, which 
was determined by the attending physician on a patient by patient basis following standard clinical assessment 
 criteria43. Follow-up time was censored on May 25, 2020 so that each patient had at least 30 days of observation. 
The study was approved by the Ethical Committee of Hospital Clínic (HCB/2020/0353) and written informed 
consent was obtained from all patients. All research was performed in accordance with Regulation EU 2016/679 
of the European Parliament and of the Council of April 27, 2016 on the protection of individuals.
Data collection. Cases were identified by daily review of hospital attendance logs in electronic medical records. 
Likewise, demographics, smoking exposure, coexisting conditions, treatment received during the last two weeks 
before hospitalization, need for ICU admission, complications or death during the clinical course, and thera-
peutic management interventions were obtained by reviewing electronic medical records. On the other hand, 
perinatal (birth weight and gestational age at delivery) and childhood (“asthma” or other respiratory disease in 
childhood) data were obtained by a face-to-face or telephone interview. Birth weight centiles were calculated 
adjusted by gender and gestational age at birth according to local  standards44. LBW was defined as birth weight 
equal or below 2500 g14. Fetal growth restriction was defined as a birth weight below the 10th centile for gesta-
tional  age45 and preterm delivery as born before 37 weeks of  gestation46.
Validation dataset. Study design, setting and population. To validate externally the performance of the 
prognostic algorithm created by the development cohort, we collected independent data from self-selected 
volunteers who declared laboratory-confirmed SARS-CoV-2 infection through an anonymous multilingual 
(Spanish, Catalan, Italian, English and French) online survey (Limey Survey GmbH, Germany). The survey 
was disseminated via email and social media, and it was open and free for all subjects who self-reported to have 
laboratory confirmed COVID-19. Demographic information, coexisting conditions, perinatal and childhood 
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data, COVID-19 related symptoms and need for hospitalization or admission to ICU were collected (voluntary 
sampling) using an anonymous web-based cross-sectional survey from April 1 to May 31, 2020.
Statistical analysis. Results are presented as counts (percentage) or mean (SD) as appropriate. Our aim 
was to determine whether being born LBW increases susceptibility to severe COVID-19 in non-elderly adults. 
Our main outcome measure was admission to ICU for COVID-19. Our main exposure measure was LBW 
defined as birth weight ≤ 2500 g. Other exposure measures were age, sex, body mass index, smoking status, pres-
ence of comorbidities (hypertension, cardiovascular disease, diabetes mellitus, obesity, chronic lung disease and 
malignancy), fetal growth restriction (defined as birth weight below 10th centile), prematurity (defined as deliv-
ery occurring before 37 weeks) and childhood lung disease. Variables with p < 0.05 on univariate analyses were 
entered in the multivariate logistic regression analysis to determine independent risk factors for ICU admission. 
A forward stepwise selection algorithm was applied to select the final model in the development dataset. Odds 
ratio and 95% confidence interval (95% CI) were calculated. Hosmer and Lemeshow test were used to assess the 
goodness of fit of the final  model47. Analysis of the Receiver Operating Curve (ROC) was used to evaluate the 
predictive performance of the model in the development datasets and the optimal cut-off was computed using 
Youden  criteria48. The model determined in the development dataset was used to predict ICU admission in the 
validation dataset and we report the statistical parameters for development and validation. All p-values are two-
sided and considered statistically significant if < 0.05. Data were analysed with SPSS v26 and R software version 
3.6.2 (R project for statistical computing, Vienna, Austria).
Received: 10 September 2020; Accepted: 5 January 2021
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